Following the FDA approval, PFE's Hympavzi becomes the first hemophilia medicine approved in the United States to be ...

HYMPAVZI is the first and only approved anti-tissue factor pathway inhibitor in the US for haemophilia A or B treatment.

The FDA granted the approval of Hympavzi to Pfizer Inc.

Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...

Pfizer announced on Friday that the U.S. Food and Drug Administration has granted approval for its once-weekly injection ...

Pfizer’s Hympavzi receives US FDA approval to treat adults and adolescents with haemophilia A or B without inhibitors: New York Monday, October 14, 2024, 18:00 Hrs [IST] Pfizer ...

The once-weekly injectable joins one-shot haemophilia B gene therapy Beqvez (fidanacogene elaparvovec) in Pfizer’s portfolio, ...

The FDA has approved a new preventive treatment for people with certain types of hemophilia that can reduce bleeding episodes, sometimes down to just a few per year.

TSMC is planning new factories in Europe focused on AI chips after starting construction on its first plant in Dresden, ...

Inventiva will gain a new chairman following the deal as it presses ahead with a Phase III trial for its lead asset.

Daiichi Sankyo and AstraZeneca's ENHERTU has been conditionally approved by China's NMPA for a specific type of NSCLC.

Eating a handful of nuts each day was found to play a "protective role", researchers have theorised, due to multiple effects ...